These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22160228)

  • 1. [Malignant lymphoma of the skin: update on diagnostics and therapy of primary cutaneous B-cell lymphoma].
    Hallermann C; Niermann C; Fluck M; Fischedick AR; Schulze HJ
    Hautarzt; 2011 Dec; 62(12):947-58. PubMed ID: 22160228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management.
    Sokol L; Naghashpour M; Glass LF
    Cancer Control; 2012 Jul; 19(3):236-44. PubMed ID: 22710899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of cutaneous B-cell lymphoma: recommendations of the French cutaneous lymphoma study group].
    Grange F; D'Incan M; Ortonne N; Dalac S; Laroche L; Beylot-Barry M; Delfau-Larue MH; Vergier B; Bagot M;
    Ann Dermatol Venereol; 2010; 137(8-9):523-31. PubMed ID: 20804896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
    Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
    Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and Management of Cutaneous B-Cell Lymphomas.
    Malachowski SJ; Sun J; Chen PL; Seminario-Vidal L
    Dermatol Clin; 2019 Oct; 37(4):443-454. PubMed ID: 31466585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
    Massengale WT; McBurney E; Gurtler J
    J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
    Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S
    Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880
    [No Abstract]   [Full Text] [Related]  

  • 8. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
    Senff NJ; Noordijk EM; Kim YH; Bagot M; Berti E; Cerroni L; Dummer R; Duvic M; Hoppe RT; Pimpinelli N; Rosen ST; Vermeer MH; Whittaker S; Willemze R; ;
    Blood; 2008 Sep; 112(5):1600-9. PubMed ID: 18567836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.
    Nicolay JP; Wobser M
    J Dtsch Dermatol Ges; 2016 Dec; 14(12):1207-1224. PubMed ID: 27992127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous B-cell lymphomas: 2013 update on diagnosis, risk-stratification, and management.
    Wilcox RA
    Am J Hematol; 2013 Jan; 88(1):73-6. PubMed ID: 23379008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
    Fernández-Guarino M; Ortiz-Romero PL; Fernández-Misa R; Montalbán C
    Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous primary B-cell lymphomas: from diagnosis to treatment.
    Lima M
    An Bras Dermatol; 2015; 90(5):687-706. PubMed ID: 26560215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cutaneous B-cell lymphoma].
    Cortés B; Prins C
    Rev Med Suisse; 2014 Apr; 10(424):738, 740-3. PubMed ID: 24772806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].
    Lamos C; Dippel E
    Hautarzt; 2017 Sep; 68(9):727-739. PubMed ID: 28815289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management.
    Wilcox RA
    Am J Hematol; 2018 Nov; 93(11):1427-1430. PubMed ID: 30039522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea.
    Kim MJ; Hong ME; Maeng CH; Jung HA; Hong JY; Choi MK; Kim SJ; Ko YH; Kim WS
    Int J Hematol; 2015 Mar; 101(3):273-8. PubMed ID: 25552248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential diagnosis between primary cutaneous large B-cell lymphoma and cutaneous follicular lymphoma: prognostic and therapeutic implications.
    Fernandez-Flores A; Smucler-Simonovich A; Escalante F; Manjon JA
    Am J Dermatopathol; 2011 Dec; 33(8):819-26. PubMed ID: 22042259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary lymphoma of the larynx: new diagnostic and therapeutic approaches.
    Nayak JV; Cook JR; Molina JT; Branch MP; Branstetter BF; Ferris RL; Myers EN
    ORL J Otorhinolaryngol Relat Spec; 2003; 65(6):321-6. PubMed ID: 14981324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intralesional rituximab for cutaneous B-cell lymphoma.
    Paul T; Radny P; Kröber SM; Paul A; Blaheta HJ; Garbe C
    Br J Dermatol; 2001 Jun; 144(6):1239-43. PubMed ID: 11422050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma.
    Dreyling M; Buske C; Hiddemann W
    Ann Oncol; 2005; 16 Suppl 2():ii99-104. PubMed ID: 15958485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.